These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37377552)

  • 1. Exploring potential applications of measles and rubella microarray patches (MR-MAPs): use case identification.
    Malvolti S; Ko M; Menozzi-Arnaud M; Mantel C; Jarrahian C; Amorij JP; Giersing B; Hasso-Agopsowicz M
    Front Public Health; 2023; 11():1165110. PubMed ID: 37377552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches.
    Soble A; Ko M; Gilchrist S; Malvolti S; Hasso-Agopsowicz M; Giersing B; Amorij JP; Jarrahian C; El Sheikh F; Menozzi-Arnaud M; Scarna T
    Vaccine; 2024 Feb; 42(6):1230-1246. PubMed ID: 38326130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the future global dose demand for measles-rubella microarray patches.
    Ko M; Malvolti S; Cherian T; Mantel C; Biellik R; Jarrahian C; Menozzi-Arnaud M; Amorij JP; Christiansen H; Papania MJ; Meltzer MI; Masresha BG; Pastor D; Durrheim DN; Giersing B; Hasso-Agopsowicz M
    Front Public Health; 2022; 10():1037157. PubMed ID: 36726626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges.
    Hasso-Agopsowicz M; Crowcroft N; Biellik R; Gregory CJ; Menozzi-Arnaud M; Amorij JP; Gilbert PA; Earle K; Frivold C; Jarrahian C; Mvundura M; Mistilis JJ; Durrheim DN; Giersing B
    Front Public Health; 2022; 10():809675. PubMed ID: 35309224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa.
    Richardson LC; Moss WJ
    Pan Afr Med J; 2020; 35(Suppl 1):3. PubMed ID: 32373254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.
    Fu H; Abbas K; Malvolti S; Gregory C; Ko M; Amorij JP; Jit M
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37949503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
    Prausnitz MR; Goodson JL; Rota PA; Orenstein WA
    Curr Opin Virol; 2020 Apr; 41():68-76. PubMed ID: 32622318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.
    Goodson JL; Rota PA
    Drug Deliv Transl Res; 2022 May; 12(5):959-967. PubMed ID: 35211868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
    Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
    BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
    Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
    PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray patches: scratching the surface of vaccine delivery.
    Choo JJY; McMillan CLD; Young PR; Muller DA
    Expert Rev Vaccines; 2023; 22(1):937-955. PubMed ID: 37846657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
    Baker B; Bermingham IM; Leelasena I; Hickling J; Young PR; Muller DA; Forster AH
    Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
    Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
    PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
    Adigweme I; Akpalu E; Yisa M; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Njie A; Bruce A; Royals M; Goodson JL; Prausnitz MR; McAllister D; Rota PA; Henry S; Clarke E
    Trials; 2022 Sep; 23(1):775. PubMed ID: 36104719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016.
    Ismail A; Tabu C; Onuekwusi I; Otieno SK; Ademba P; Kamau P; Koki B; Ngatia A; Wainaina A; Davis R
    Pan Afr Med J; 2017; 27(Suppl 3):16. PubMed ID: 29296151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunization Programme and Coverage against Measles and Rubella in Spain. Challenges for Achieving their Elimination].
    Limia Sánchez A; Molina Olivas M
    Rev Esp Salud Publica; 2015; 89(4):357-64. PubMed ID: 26580791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of coverage of MR vaccination, after supplementary immunization activities in a rural area of South India: a rapid immunization coverage survey.
    Newtonraj A; Vincent A; Selvaraj K; Manikandan M
    Rural Remote Health; 2019 Sep; 19(3):5261. PubMed ID: 31529972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.